Systemic Anti-Cancer Therapy Regimen Library
Gynaecological Regimens
Published
Name
|
Version
|
Date
|
|---|---|---|
| GYN - pembrolizumab Q3W [flat dosing] | 1.0.0 | 19/08/2022 |
| GYN - pembrolizumab Q3W [weight based dosing] | 1.0.0 | 19/08/2022 |
| GYN - pembrolizumab Q6W [flat dosing] | 1.0.0 | 19/08/2022 |
| GYN Ovarian germ cell tumour - BEP [bleomycin, etoposide and cISplatin] | 3.0.0 | 19/02/2025 |
Cervical Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| GYN CX Advanced - cARBOplatin and PACLItaxel | 1.0.0 | 19/08/2022 |
| GYN CX Advanced - cARBOplatin, PACLItaxel and beVACizumab | 1.0.0 | 19/08/2022 |
| GYN CX Advanced - cARBOplatin, PACLItaxel and pembrolizumab | 1.0.0 | 03/04/2025 |
| GYN CX Advanced - cARBOplatin, PACLItaxel, beVACizumab and pembrolizumab | 1.0.0 | 11/10/2024 |
| GYN CX Advanced - cISplatin and PACLItaxel | 1.0.0 | 29/08/2022 |
| GYN CX Advanced - cISplatin, PACLItaxel and beVACizumab | 1.0.0 | 10/10/2023 |
| GYN CX Advanced - cISplatin, PACLItaxel and pembrolizumab | 1.0.0 | 10/10/2023 |
| GYN CX Advanced - cISplatin, PACLItaxel, beVACizumab and pembrolizumab | 1.0.0 | 23/10/2023 |
| GYN CX Locally advanced - cARBOplatin [Q1W] chemoradiation | 1.0.0 | 20/10/2022 |
| GYN CX Locally advanced - cISplatin [Q1W] chemoradiation | 2.0.0 | 13/08/2023 |
Endometrial Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only] | 2.0.0 | 13/08/2023 |
| GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel | 2.0.0 | 02/10/2023 |
| GYN END Advanced - cARBOplatin and PACLItaxel | 1.0.0 | 19/08/2022 |
| GYN END Advanced - cARBOplatin, PACLItaxel and dostarlimab | 1.0.0 | 20/01/2025 |
| GYN END Advanced - cARBOplatin, PACLItaxel and pembrolizumab | 1.0.0 | 20/01/2025 |
| GYN END Advanced - cARBOplatin, PACLItaxel and trastuzumab | 1.0.0 | 21/01/2025 |
| GYN END Advanced - leNVAtinib and pembrolizumab Q3W [flat dosing] | 1.0.0 | 23/08/2022 |
| GYN END Advanced - meDROXYPROGESTERone acetate | 1.0.0 | 29/08/2022 |
GTD Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| GYN GTD - daCTINomycin [low risk] | 1.0.0 | 23/08/2022 |
| GYN GTD - EMA-CO [etoposide, metHOTREXATe, daCTINomycin - CYCLOPHOSPHamide and vinCRISTine] [high risk] | 1.0.0 | 25/07/2025 |
| GYN GTD - EP [etoposide and cISplatin] [very high risk] | 1.0.0 | 28/09/2022 |
| GYN GTD - EP-EMA [etoposide, ciSplatin - etoposide, metHOTREXATe and daCTINomycin] [high risk] | 1.0.0 | 25/07/2025 |
| GYN GTD - metHOTREXATe [low risk] | 1.0.0 | 19/09/2023 |
| GYN GTD - TP-TE [PACLItaxel, cISplatin - PACLItaxel and etoposide] [relapsed or high risk] | 1.0.0 | 19/09/2023 |
Ovarian Regimens
Published
Vulval Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| GYN VUL Advanced - CARBOplatin [Q1W] chemoradiation | 1.0.0 | 28/10/2022 |
| GYN VUL Advanced - ciSplatin [Q1W] chemoradiation | 1.0.0 | 10/07/2023 |